1. Home
  2. SLN vs ATGL Comparison

SLN vs ATGL Comparison

Compare SLN & ATGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$7.10

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Technology Group Limited

ATGL

Alpha Technology Group Limited

HOLD

Current Price

$14.10

Market Cap

232.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
ATGL
Founded
1994
2017
Country
United Kingdom
Hong Kong
Employees
116
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
236.2M
232.1M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
SLN
ATGL
Price
$7.10
$14.10
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$42.60
N/A
AVG Volume (30 Days)
426.8K
967.0
Earning Date
05-07-2026
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.54
$9.01
52 Week High
$8.40
$50.00

Technical Indicators

Market Signals
Indicator
SLN
ATGL
Relative Strength Index (RSI) 54.38 38.04
Support Level $5.76 $9.01
Resistance Level $7.53 $20.25
Average True Range (ATR) 0.58 0.48
MACD 0.03 -0.13
Stochastic Oscillator 60.25 28.13

Price Performance

Historical Comparison
SLN
ATGL

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About ATGL Alpha Technology Group Limited

Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.

Share on Social Networks: